Outlook on the Global Neurodegenerative Disorder Therapeutics Industry to 2030 – Featuring Biogen, Pfizer, Novartis & Sanofi Among Others – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Neurodegenerative Disorder Therapeutics Market Global Report 2020-30” report has been added to ResearchAndMarkets.com’s offering.

The global neurodegenerative disorder therapeutics market was worth $13.35 billion in 2019. It is expected to grow at a compound annual growth rate (CAGR) of 8.12% and reach $18.23 billion by 2023.

The neurodegenerative disorder therapeutics market has been geographically segmented into North America, Western Europe, Asia-Pacific, Eastern Europe, South America and Middle East & Africa. North America was the largest region in 2019 and Europe was the fastest growing region in 2019.

Neurodegenerative Disorder Therapeutics Market Global Report 2020-30 from the author provides the strategists, marketers and senior management with the critical information they need to assess the global neurodegenerative disorder therapeutics market.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 12+ geographies.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market research findings.
• Benchmark performance against key competitors.
• Utilize the relationships between key data sets for superior strategizing.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3 working days of order.

The neurodegenerative disorder therapeutics market covered in this report is segmented by indication type into Parkinson’s disease, Alzheimer’s disease, multiple sclerosis, Huntington disease, other indications. It is also segmented by drug type into n- methyl- d- aspartate receptor, selective serotonin reuptake inhibitor, dopamine inhibitors, others and by distribution into hospital pharmacy, retail pharmacy, online pharmacy.

Increased prevalence of neurodegenerative among the global population contributes to the growth of neurodegenerative disorder therapeutics market. The increase in the number of geriatric population, attributes to the increased prevalence of neurodegenerative disorders. According to World Population Prospects in 2017, the number of people above 60 years of age will increase from 962 million in 2017 to 2.1 billion in 2050 and it is expected that people aged over 80 years will triple from 137 million in 2017 to 425 million in 2050.

According to the Alzheimer’s Association, around 5.8 million Americans are suffering with Alzheimer disease and this number is projected to rise to around 14 million by 2050. The increased prevalence of neurodegenerative diseases among the ageing population increases the demand for neurodegenerative disorder therapeutics thereby driving the market.

High rates of failure in clinical trials and research and development (R&D) have always been a major challenge in the neurodegenerative disorder therapeutics market. Companies are continuously investing in R&D to develop treatments for neurodegenerative diseases but currently very few treatments are approved for neurodegenerative disorders. According to a study, researchers found out that between 2002 to 2012, only 244 compounds in 413 clinical trials for Alzheimer’s disease passed through but only one compound was approved. This failure entitled Alzheimer’s disease drugs to the highest rates of failure at 99.6% when compared to any other disease, including cancer, which has a failure rate at 81%.

Key Topics Covered:

1. Executive Summary

2. Neurodegenerative Disorder Therapeutics Market Characteristics

3. Neurodegenerative Disorder Therapeutics Market Size And Growth

3.1. Global Neurodegenerative Disorder Therapeutics Historic Market, 2015 – 2019, $ Billion

3.1.1. Drivers Of The Market

3.1.2. Restraints On The Market

3.2. Global Neurodegenerative Disorder Therapeutics Forecast Market, 2019 – 2023F, 2025F, 2030F, $ Billion

3.2.1. Drivers Of The Market

3.2.2. Restraints On the Market

4. Neurodegenerative Disorder Therapeutics Market Segmentation

4.1. Global Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

4.2. Global Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

4.3. Global Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

5. Neurodegenerative Disorder Therapeutics Market Regional And Country Analysis

5.1. Global Neurodegenerative Disorder Therapeutics Market, Split By Region, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

5.2. Global Neurodegenerative Disorder Therapeutics Market, Split By Country, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

Companies Mentioned

• Biogen
• Pfizer
• Novartis
• Sanofi
• Teva Pharmaceutical
• UCB
• Hoffmann- La Roche Ltd
• ACADIA Pharmaceuticals Inc.
• Lundeck A/S
• Boehringer Ingeiheim International GmbH
• Merck Serono
• Orion Pharma Ltd
• Mitsubishi Tanabe Pharma America
• Allergan
• GlaxoSmith Kline PLC
• AbbVie
• Eli Lilly
• Celgene
• Neuro- Hitech Inc.
• Bayer Schering Pharma AG
• Amarin Corporation
• AstraZeneca
• Alector
• Yumanity Therapeutics
• Yangtze River Pharmaceutical Group
• Chongqing Zein Pharmaceutical
• Eisai
  

For more information about this report visit https://www.researchandmarkets.com/r/obxzmt

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900